TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06163664

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of chatGPT for 1 week
Description: Use of chatGPT for 1 week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of chatGPT for 1 week
Description: Use of chatGPT for 1 week
Study: NCT05462938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of propofol
Description: Sedation under continuous infusion of propofol. Small doses of fentanyl will be administered if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of dexmedetomidine
Description: Sedation under continuous infusion of dexmedetomidine. Small doses of fentanyl will be administered if needed.
Study: NCT05021133

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tele-Navi LCS
Description: Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS using a video or telephone call
Study: NCT05536973

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-022
Description: A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-022
Description: A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
Study: NCT06040515

Intervention type: DRUG
Intervention: Probiotic Formula
Description: Capsule with 25 billion live strains of Escherichia coli Nissle 1917
Study: NCT05096364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111/Placebo
Description: After loading dose, investigational drug was administered subcutaneously up to 60 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111/Placebo
Description: After loading dose, investigational drug was administered subcutaneously up to 60 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111/Placebo
Description: After loading dose, investigational drug was administered subcutaneously up to 60 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111/Placebo
Description: After loading dose, investigational drug was administered subcutaneously up to 60 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AK111/Placebo
Description: After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
Study: NCT04757025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: In 27 patients ventilation will be guided with an Electrical Impedance Tomography system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral arterial Saturation
Description: The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone
Study: NCT05808374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635
Description: 50mg HRS-5635；100mg HRS-5635；200mg HRS-5635；400mg HRS-5635；600mg HRS-5635；800mg HRS-5635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635
Description: 100mg HRS-5635，Q4W；200mg HRS-5635 ，Q4W；400mg HRS-5635，Q4W；200mg HRS-5635, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635
Description: 200mg HRS-5635，Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06196268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core strengthening exercise
Description: CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: Pilates includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks
Study: NCT05808374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04928612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1018
Description: CBP-1018 for injection, IV infusion
Study: NCT05583175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax plus RIC
Description: Eligible patients will receive Venetoclax plus RIC regimen allogeneic transplantation. The treatment regimen is: Venetoclax 100mg/d - 10d, 200mg/d - 9d (first use and NR or untreated MDS), 400mg/d, - 8d\~ - 2d (7d); Fludarabine: 30mg/m2/d, - 6d\~-2d (5d), Cytarabine: 1g/m2/d, - 6d\~-2d (5d) Busulfan: 3.2mg/m2/d, - 6d\~-5d (2d), TBI: 3 Gray, - 1d.
Study: NCT06468085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: premixed Bioceramic NeoPUTTY®
Description: Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine™
Description: Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic or Biodentine™ according to the corresponding group then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: Root canal treatment will be performed to the control group followed by composite restoration. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
Study: NCT05823311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, tislelizumab, gemcitabine and cisplatin
Description: Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine and cisplatin
Description: Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
Study: NCT04974164

Intervention type: BIOLOGICAL
Intervention: Inactivated COVID-19 Vaccine
Description: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen

Intervention type: BIOLOGICAL
Intervention: Inactivated COVID-19 Vaccine
Description: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen
Study: NCT06026826

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial alternating current stimulation
Description: tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial alternating current stimulation
Description: Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
Study: NCT05043207

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: uAud
Description: Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Traditional audiometry
Description: Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure
Study: NCT04767841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000mg tablet plus celecoxib 200 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet plus celecoxib 200 mg capsule
Study: NCT05705739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrolaminar block
Description: curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
Study: NCT06409481

Intervention type: DRUG
Intervention: Antineoplastic Agents
Description: small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics
Study: NCT05517577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour Change Communication and Male involvement intervention
Description: For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
Study: NCT06487897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimal laser keratoplasty
Description: Laser
Study: NCT04902040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05138705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Virus Split Vaccine
Description: 0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
Study: NCT05953519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
Study: NCT04902040

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06128239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Text message version of Motto's Caring Contacts intervention. The study will compare two versions of text-based Caring Contacts: two-way messages, to which participants can respond to receive text-based support from follow-up specialists, and one-way text messages, to which participants cannot respond.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Text message version of Motto's Caring Contacts intervention. The study will compare two versions of text-based Caring Contacts: two-way messages, to which participants can respond to receive text-based support from follow-up specialists, and one-way text messages, to which participants cannot respond.
Study: NCT05282537

Intervention type: BEHAVIORAL
Intervention: In person academic activities
Description: All participants will perform academic activities in person from March to December, 2022
Study: NCT04610801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray
Description: Randomized to placebo and Xlear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Spray
Description: Randomized to placebo and Xlear
Study: NCT05898828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.
Study: NCT05898828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (5 mg) self-administered on Days -14 and -7 prior to the first vaccination cycle, then entinostat (3 mg) self-administered on Days 1, 8, 15, and 22 of each vaccine cycle (Cycles 1-6). Entinostat continuation for subjects with immunologic response and NED during additional 2 vaccine injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (5 mg) self-administered on Days -14 and -7 prior to the first vaccination cycle, then entinostat (3 mg) self-administered on Days 1, 8, 15, and 22 of each vaccine cycle (Cycles 1-6). Entinostat continuation for subjects with immunologic response and NED during additional 2 vaccine injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide(R) ISA-51 VG Adjuvant
Description: H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide(R) ISA-51 VG Adjuvant
Description: H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1299 Cell Lysates
Description: H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1299 Cell Lysates
Description: H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
Study: NCT05268224

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Strip
Description: A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
Study: NCT05388279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS012
Description: JS012, i.v., q3w

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS012 combine with chemotherapy
Description: JS012 i.v., q3w combine with chemotherapy
Study: NCT05396027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-guided deep breathing
Description: 2 weeks of audio-guided deep breathing for participants (healthy and physically disabled)
Study: NCT04894825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M108
Description: Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M108
Description: IV infusion Q3W. (21-day cycles)
Study: NCT05739838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolase ;Low Level Laser
Description: Low Level laser ,940 nm
Study: NCT04680000

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)
Description: BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)
Description: BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
Study: NCT05232032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nociceptin Receptor Antagonist
Description: Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nociceptin Receptor Antagonist
Description: Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aversive stimuli
Description: As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aversive stimuli
Description: As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aversive stimuli
Description: As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aversive stimuli
Description: As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
Study: NCT05270187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial massage and facial expression exercises
Description: Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.